Johnson & Johnson $JNJ is Aull & Monroe Investment Management Corp's 10th Largest Position

Key Points

• Aull & Monroe Investment Management Corp has reduced its stake in Johnson & Johnson by 7.9%, making it the firm's 10th largest position at approximately $4.45 million.
• Johnson & Johnson reported earnings of $2.26 per share for the most recent quarter, with analysts forecasting an annual EPS of 10.58.
• The company declared a quarterly dividend of $1.30 to be issued on December 9th, reflecting an annualized yield of 2.7%.

Aull & Monroe Investment Management Corp lessened its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,163 shares of the company's stock after selling 2,506 shares during the quarter. Johnson & Johnson makes up about 2.4% of Aull & Monroe Investment Management Corp's holdings, making the stock its 10th biggest holding. Aull & Monroe Investment Management Corp's holdings in Johnson & Johnson were worth $4,455,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Wingate Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Wingate Wealth Advisors Inc. now owns 1,828 shares of the company's stock valued at $279,000 after acquiring an additional 216 shares in the last quarter. Planned Solutions Inc. lifted its position in Johnson & Johnson by 2.3% in the 2nd quarter. Planned Solutions Inc. now owns 4,148 shares of the company's stock worth $634,000 after buying an additional 93 shares in the last quarter. Financial Synergies Wealth Advisors Inc. purchased a new stake in Johnson & Johnson in the 2nd quarter worth approximately $1,016,000. MB Levis & Associates LLC lifted its position in Johnson & Johnson by 1.2% in the 2nd quarter. MB Levis & Associates LLC now owns 11,676 shares of the company's stock worth $1,783,000 after buying an additional 135 shares in the last quarter. Finally, First Bancorp Inc ME lifted its position in Johnson & Johnson by 4.7% in the 2nd quarter. First Bancorp Inc ME now owns 8,734 shares of the company's stock worth $1,334,000 after buying an additional 395 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $193.78 on Tuesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The firm's fifty day simple moving average is $180.89 and its 200 day simple moving average is $165.18. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $466.68 billion, a PE ratio of 18.70, a PEG ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The business had revenue of $24.02 billion for the quarter. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson's dividend payout ratio is 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. UBS Group increased their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a "buy" rating in a research report on Tuesday, October 14th. Royal Bank Of Canada restated an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a "hold" rating in a research note on Wednesday, October 15th. Weiss Ratings upgraded shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Finally, Daiwa Capital Markets upgraded shares of Johnson & Johnson from a "neutral" rating to an "outperform" rating and set a $203.00 price target on the stock in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $200.06.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.